European Commission Approves Doxecitine and Doxribtimine as First Therapy for TK2d The European Commission has approved doxecitine and doxribtimine, the first therapy for pediatric and adult patients with TK2d.

The @ec.europa.eu has granted marketing authorization to #Doxecitine and #Doxribtimine (#Kygevvi®) under exceptional circumstances for the treatment of thymidine kinase 2 deficiency (#TK2d), pharmaceutical company UCB announced.

Read more: https://bit.ly/4tGA4uL

#RareDisease #MedSky

FDA Approves First-Ever Treatment for TK2d The combination therapy doxecitine and doxribtimine (Kygevvi®) has been approved by the US Food and Drug Administration (FDA) as the first and only

The combination therapy #Doxecitine and #Doxribtimine (#Kygevvi®) has been approved by the US Food and Drug Administration (FDA) as the first and only treatment for thymidine kinase 2 deficiency (#TK2d), UCB announced.

Learn more ➡️: https://bit.ly/4nGTlZe

#RareDisease #MedSky #RareSky